查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856777

急性缺血性腦中風診斷市場（按產品類型、檢測類型、疾病類型、技術和最終用戶分類）－2025-2032年全球預測

Acute Ischemic Stroke Diagnosis Market by Product Type, Test Type, Disease Type, Technology, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，急性缺血性腦中風診斷市場規模將達到 64.7 億美元，複合年成長率為 6.98%。

關鍵市場統計數據
基準年 2024 37.7億美元
預計年份：2025年 39.9億美元
預測年份 2032 64.7億美元
複合年成長率 (%) 6.98%

明確緊迫的臨床優先事項和技術促進因素，以重塑急性缺血性腦中風的診斷並為策略決策提供依據

急性缺血性腦中風仍然是全球範圍內導致發病率和死亡率的主要原因之一，因此需要快速、實證的診斷策略來最佳化臨床療效。新的生物標記、先進的影像學技術和床邊診斷解決方案正在整合到時間緊迫的診斷領域，以縮短診斷時間並實現更有針對性的干涉。隨著臨床團隊不斷完善分流通訊協定，院前識別、院內診斷和介入準備之間的相互作用對於降低殘疾率和改善康復進程至關重要。

隨著人們對個人化醫療的期望日益成長，診斷領域的相關人員必須權衡速度、準確性和資源投入。影像和實驗室診斷技術的進步拓展了臨床醫生可用的工具，但也帶來了採購、培訓和工作流程整合的複雜性。因此，醫療機構領導者和臨床主任面臨著投資優先事項的決策，這些決策將直接影響患者就診量、治療時間長度和跨部門協作。以下章節概述了正在影響急性缺血性腦中風診斷的技術、政策和實踐方面的關鍵轉變，並重點介紹了醫療系統、設備製造商和診斷實驗室需要考慮的策略因素。

探索正在加速診斷和重塑急性缺血性腦中風管理的關鍵技術進步和護理路徑創新

由於技術進步、流程最佳化以及以速度和準確性為優先的新型診療模式的出現，急性缺血性腦中風的診斷格局正在發生顯著變化。諸如快速CT灌注通訊協定和增強型MRI序列等先進影像技術正日益融入超急性期診療流程，用於區分胼胝體組織與不可逆損傷區域，並為再灌注治療決策提供依據。同時，可攜式影像設備和遠端醫療平台已將診斷範圍擴展至偏遠地區，使遠距專家能夠指導時間緊迫的干涉措施。

同時，分子診斷和血液生物標記正從研究領域走向臨床應用，有望對病因進行分層，並識別出哪些患者對特定的再灌注策略無效。床邊檢測技術正在縮短關鍵參數的周轉時間，並支援在急診和院前救護環境中更早做出臨床決策。這些技術進步，加上諸如直接進行CT分流、移動中風單位和簡化傳輸通訊協定等診療路徑的創新，旨在縮短從入院到溶栓治療以及從入院到腹股溝穿刺的時間間隔。這些轉變提高了診斷準確性，並釋放了以患者為中心、循證的急性中風治療的潛力。

評估海關制度的變化和跨境貿易的複雜性如何影響急性中風診斷的籌資策略和供應鏈韌性

關稅政策和跨境貿易動態的變化會對用於急性缺血性腦中風診斷的診斷設備和耗材的供應和成本結構產生重大影響。 2025年，不斷增加的關稅壓力衝擊了醫療影像組件、實驗室試劑和特殊耗材的供應鏈，迫使採購團隊重新評估供應商關係和籌資策略。因此，醫療機構尋求供應鏈多元化，並提高關鍵物資的庫存彈性，以避免重症患者的醫療服務中斷。

這項轉變促使醫療服務提供者和診斷試劑供應商重新評估總到岸成本，並探索其他採購方式，例如區域製造夥伴關係和一體化採購框架。臨床醫生和管理人員必須權衡短期成本上漲的可能性與維持快速診斷吞吐量的臨床需求，因為這直接影響患者的治療效果。為此，一些醫療系統優先考慮減少對進口耗材依賴的資本投資，而另一些系統則透過談判達成長期供應協議來穩定價格並確保醫療服務的連續性。整體而言，關稅相關的不利因素促使供應鏈管理採取更具策略性的方法，並加速考慮本地生產和冗餘計畫。

整合產品、測試、疾病、技術和最終用戶觀點，以識別差異化的採用路徑和臨床效用促進因素。

透過多角度細分市場，可以揭示不同的臨床和營運需求如何驅動需求和應用模式。依產品類型分類，診斷路徑包括血液生物標記檢測、頸動脈超音波、電腦斷層掃描（CT）和磁振造影（MRI）等影像學檢查以及腦電圖（EEG），每種方法都發揮互補作用，從快速分診到病因分類均有涉及。按檢測類型分類，臨床工作流程依賴實驗室檢測和代謝指標檢測，其中包括血液檢測和影像學評估，這些檢測有助於選擇急性治療方案。按疾病類型分類，栓塞性中風、腔隙性中風和血栓性中風的診斷重點各不相同，因為每種病理對影像學選擇、生物標記解讀和二級預防策略都有其獨特的影響。按技術分類，檢測工具涵蓋基於生物標記的檢測和就地檢驗平台，它們的周轉時間、所需基礎設施和操作人員培訓各不相同。在最終用戶中，門診手術中心、診斷中心、醫院/診所和實驗室將根據不同的使用情況、監管限制和臨床期望做出採用和採購決定。

整合這種細分觀點，有助於相關人員根據不同使用者類型和疾病特徵的具體需求，調整產品開發、臨床檢驗和商業化策略。例如，針對照護現場最佳化的解決方案優先考慮快速週轉和簡化的工作流程，而影像技術投資則側重於吞吐量、與卒中診療方案的兼容性以及與介入團隊的整合。這種多維度的觀點有助於在各種臨床環境中進行有針對性的創新和更有效的部署。

檢驗基礎設施、臨床通訊協定和實施動態方面的區域差異，以便在不同的醫療環境中製定相應的診斷策略。

區域動態對急性缺血性腦中風的診斷方法應用、基礎設施投資和臨床方案有顯著影響。在美洲，先進的三級醫療中心和綜合醫療網路主導高階影像、移動卒中單元和生物標記研究的應用，而同一區域內的農村地區仍然面臨著遠端醫療匱乏的挑戰，因此需要遠距醫療和中心輻射式醫療模式。在歐洲、中東和非洲，醫療體系各不相同，一方面是都市區地區，這些地區以卓越的醫療水平為導向，並得到公共衛生舉措的支持，重點發展卒中網路；另一方面是資源匱乏的地區，這些地區需要切實可行、可擴展的診斷解決方案。在亞太地區，醫療基礎設施的快速現代化和對診斷影像的大量投資正在擴大醫療能力，但報銷機制和醫護人員配備的差異導致先進診斷技術的應用並不均衡。

這些區域差異會影響供應商在監管核准、本地化服務模式以及與衛生署的夥伴關係所採取的優先順序。此外，疾病流行模式、急救醫療服務的成熟度以及當地的培訓計畫也會影響採用先進診斷工作流程的可行性。因此，企業和醫療系統必須制定量身定做的策略，充分考慮基礎設施的成熟度、臨床實踐規範以及不同環境下醫護人員和患者的實際需求。

分析競爭格局，看整合影像、快速偵測和軟體驅動的工作流程如何重新定義診斷差異化。

在急性缺血性腦中風診斷領域，主要企業正致力於推廣差異化的產品組合，包括影像硬體、實驗室檢測、照護現場平台和整合軟體解決方案。同時，創新參與企業則專注於生物標記發現、快速檢測以及用於急診和院前急救的微型診斷設備。影像設備供應商、檢測開發人員和臨床機構之間的夥伴關係日益普遍，從而能夠協同開發整合診斷路徑，加速臨床檢驗和應用。

競爭也反映了規模與專業化之間的平衡。大型製造商利用其全球服務網路和已建立的安裝基礎，銷售整合掃描器、資訊學和培訓的捆綁式解決方案。同時，靈活的新興企業通常專注於特定領域的性能優勢，例如超快速檢測或人工智慧影像分析，並致力於透過有針對性的臨床試驗和策略聯盟來證明其臨床療效。總體而言，競爭格局獎勵互通性、對監管的積極洞察以及在診斷時間和準確性方面取得顯著改進，從而為整合和策略聯盟創造了機會。

為開發者和醫療保健領導者提供可操作的策略重點，以加速產品應用並確保持續的臨床和商業性優勢。

產業領導者應採取一系列切實可行的優先事項，在控制營運風險的同時，加速臨床應用。首先，透過投資互通性、以使用者為中心的設計以及減少實施阻力的培訓項目，使產品開發與實際臨床工作流程保持一致。其次，優先進行能夠顯著縮短診斷時間和改善治療方案選擇的臨床檢驗研究，從而增強對支付者和醫院的提案主張。第三，透過實現生產和銷售管道多元化，並談判簽訂穩定的合約以確保關鍵組件和試劑的供應，從而解決供應鏈脆弱性問題。

此外，醫療機構應儘早與支付方和監管相關人員接洽，明確報銷途徑，並規劃符合證據要求的試驗。與急救醫療服務機構、區域中風網路和學術中心進行策略合作，可以加速技術應用，並產生可靠的臨床數據。最後，醫療機構可以投資於可擴展的服務模式和管理式產品，以降低醫療系統的整體擁有成本，並考慮有針對性的商業化策略，根據最終用戶的能力對產品進行分級。這些措施的綜合運用，既能提升市場相關性，又能幫助臨床醫師更快、更準確地診斷中風。

採用嚴謹的多來源調查方法，結合臨床證據、專家見解和供應鏈分析，得出可靠的結論。

調查方法採用多源整合策略，結合臨床文獻回顧、專家訪談、技術評估和供應鏈分析，以全面展現診斷現況。證據綜合分析採用同儕審查的臨床研究、指南聲明和已發表的技術評估報告，以評估臨床效用和對工作流程的影響。透過對神經科、急診科醫生、放射科醫生、實驗室主任和採購負責人的訪談，揭示了實際操作中的限制因素和推廣應用的促進因素；同時，供應商的演示和產品數據表則提供了設備功能和服務模式的技術背景。

我們的供應鏈和政策分析依賴海關和貿易文件、採購競標資訊以及公共部門政策公告，以評估影響設備和試劑供應的因素。在適當情況下，我們借鑒了高績效卒中中心的案例，以闡明路徑重建和技術整合的最佳實踐。在整個調查方法中，我們整合了多個資訊流，以確保我們的結論能夠反映與急性缺血性腦中風診斷相關的臨床實際情況、運作限制和技術發展軌跡。

急性中風診斷有效性和患者預後受臨床、技術和操作因素共同影響的總結

總之，急性缺血性中風診斷正處於曲折點，技術創新、流程重塑和供應鏈考量正在匯聚，共同重塑臨床實踐。快速成像、新型生物標記應用和就地檢驗能夠實現更準確、更及時的決策，而區域和政策因素則影響這些技術的應用可能性和速度。積極主動地解決工作流程整合、臨床檢驗和採購彈性等問題的相關人員，將更有能力把診斷技術的進步轉化為病患預後的可衡量改善。

展望未來，持續專注於縮短治療時間，並持續提高診斷準確性，將繼續推動臨床、商業和政策領域的投資與合作。注重互通性、實證嚴謹性和適應性交付策略，將使醫療服務提供者和產業合作夥伴能夠確保下一代診斷工具在急性缺血性腦中風治療中既具有臨床價值，又具有營運永續性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過整合以人工智慧為基礎的CT灌注分析加速急性缺血性腦中風的診斷和分診
  • 部署配備可攜式CT掃描儀和遠端醫療連接的移動卒中單元，以縮短從入院到接受治療的時間。
  • 利用基於血液的生物標記組合結合人工智慧演算法快速區分缺血性卒中亞型
  • 利用雲端基礎的影像診斷平台擴展遠距中風網路，改善農村地區急性中風患者的治療效果
  • 用於即時檢測缺血性中風患者神經發炎標記的照護現場分子檢測技術取得了進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型分類的急性缺血性腦中風診斷市場

  • 血液生物標記
  • 頸動脈超音波
  • 影像診斷
    • 電腦斷層掃描（CT）掃描儀
    • 磁振造影系統
  • 腦電圖（EEG）

第9章 依偵測類型急性缺血性腦中風診斷市場

  • 實驗室檢測
    • 血液檢查
    • 影像檢查
  • 代謝指標

第10章 依疾病類型分類的急性缺血性腦中風診斷市場

  • 栓塞
  • 空白
  • 血栓性

第11章急性缺血性腦中風診斷市場（依技術分類）

  • 基於生物標記的檢測
  • 就地檢驗

第12章急性缺血性腦中風診斷市場（依最終用戶分類）

  • 門診手術中心
  • 診斷中心
  • 醫院和診所
  • 研究所

第13章急性缺血性腦中風診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章急性缺血性腦中風診斷市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國急性缺血性腦中風診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Aidoc Medical Ltd.
    • BIOTRONIK SE & Co KG
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corporation
    • Canon Medical Systems Corporation
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • GE Healthcare Technologies Inc.
    • Hitachi, Ltd.
    • Integral Diagnostics（IDX）Group
    • Johnson & Johnson Services, Inc.
    • Koninklijke Philips NV
    • Mediso Ltd.
    • Medtronic PLC
    • Merck & Co.
    • Neusoft Corporation
    • Nihon Kohden Corporation
    • Planmed Oy
    • Samsung Electronics Co. Ltd.
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Shimadzu Corporation
    • Shionogi & Co., Ltd.
    • Siemens Healthineers
    • Stryker Corporation
    • Toshiba International Corporation
Product Code: MRR-B16853776EA8

The Acute Ischemic Stroke Diagnosis Market is projected to grow by USD 6.47 billion at a CAGR of 6.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.77 billion
Estimated Year [2025] USD 3.99 billion
Forecast Year [2032] USD 6.47 billion
CAGR (%) 6.98%

Framing the urgent clinical priorities and technological drivers reshaping acute ischemic stroke diagnosis to inform strategic decision-making

Acute ischemic stroke remains a leading cause of morbidity and mortality worldwide and demands rapid, evidence-based diagnostic strategies to optimize clinical outcomes. The diagnostic landscape is evolving as time-critical pathways integrate novel biomarkers, advanced imaging modalities, and point-of-care solutions that shorten time-to-diagnosis and enable more targeted interventions. As clinical teams refine triage protocols, the interplay between pre-hospital recognition, in-hospital diagnostics, and interventional readiness has become central to reducing disability and improving recovery trajectories.

In the context of rising expectations for personalized care, diagnostic stakeholders must balance speed, accuracy, and resource intensity. Technological advances in imaging and laboratory diagnostics have expanded the tools available to clinicians, but they also introduce complexity in procurement, training, and workflow integration. Consequently, institutional leaders and clinical directors face decisions about investment priorities that directly influence patient throughput, treatment windows, and cross-disciplinary collaboration. The subsequent sections synthesize the key shifts in technology, policy, and practice that are shaping acute ischemic stroke diagnosis and highlight strategic considerations for health systems, device manufacturers, and diagnostic laboratories.

Exploring the pivotal technological advancements and care pathway innovations that are accelerating diagnosis and reshaping acute ischemic stroke management

The landscape of acute ischemic stroke diagnosis is undergoing transformative shifts driven by technological refinement, operational redesign, and emerging care models that prioritize speed and precision. Advanced imaging techniques, such as rapid CT perfusion protocols and enhanced MRI sequences, are increasingly integrated into hyperacute workflows to differentiate penumbral tissue from irreversibly damaged areas, thereby informing reperfusion decisions. At the same time, portable imaging and telemedicine platforms have extended diagnostic reach into community and rural settings, enabling remote expertise to guide time-sensitive interventions.

Concurrently, molecular diagnostics and blood-based biomarkers are moving from research settings toward clinical applicability, offering the potential to stratify etiologies and identify patients unlikely to benefit from certain reperfusion strategies. Point-of-care testing technologies are reducing turnaround times for critical parameters and supporting earlier clinical decision-making in emergency and pre-hospital environments. These technological advances are coupled with care pathway innovations such as direct-to-CT triage, mobile stroke units, and streamlined transfer protocols, all of which seek to compress door-to-needle and door-to-groin puncture intervals. Together, these shifts enhance the precision of diagnosis and expand the possibilities for patient-centered, evidence-based acute stroke care.

Assessing how shifting tariff regimes and cross-border trade complexities have influenced procurement strategies and supply chain resilience in acute stroke diagnostics

Tariff policy changes and cross-border trade dynamics can materially influence the availability and cost structure of diagnostic equipment and consumables that support acute ischemic stroke diagnosis. In 2025, heightened tariff pressures affected the supply chains for medical imaging components, laboratory reagents, and specialized disposables, prompting procurement teams to reassess vendor relationships and sourcing strategies. As a result, organizations sought to diversify supply channels and to increase inventory resilience for critical items to avoid disruptions in hyperacute care delivery.

These shifts prompted healthcare providers and diagnostics suppliers to re-evaluate total landed costs and to explore alternative sourcing arrangements, including regional manufacturing partnerships and consolidated procurement frameworks. Clinicians and administrators had to balance the potential for short-term cost increases against the clinical imperative of maintaining rapid diagnostic throughput, which is directly tied to patient outcomes. In response, some systems prioritized capital investments that reduced dependency on imported consumables, while others negotiated long-term supply contracts to stabilize prices and ensure continuity of care. Overall, tariff-related headwinds encouraged a more strategic approach to supply chain management and accelerated considerations for localized production and redundancy planning.

Integrating product, test, disease, technology, and end-user perspectives to reveal differentiated adoption pathways and clinical utility drivers

Understanding the market through multiple segmentation lenses clarifies how distinct clinical and operational needs drive demand and adoption patterns. Based on product type, diagnostic pathways incorporate blood biomarker assays, carotid ultrasound, diagnostic imaging modalities including computed tomography scanners and MRI systems, and electroencephalography, each serving complementary roles from rapid triage to etiologic classification. Based on test type, the clinical workflow relies on lab tests and metabolic panels, with lab tests further encompassing blood tests and imaging-based assessments that inform acute therapeutic choices. Based on disease type, diagnostic priorities differ for embolic, lacunar, and thrombotic strokes, as each presentation carries unique implications for imaging selection, biomarker interpretation, and secondary prevention strategies. Based on technology, detection tools span biomarker-based assays and point-of-care testing platforms, which vary in turnaround time, required infrastructure, and operator training. Based on end-user, adoption and procurement decisions are driven by ambulatory surgical centers, diagnostic centers, hospitals and clinics, and research laboratories, each with distinct volume profiles, regulatory constraints, and clinical expectations.

By synthesizing these segmentation perspectives, stakeholders can align product development, clinical validation, and commercialization strategies with the specific needs of different user types and disease presentations. For example, solutions optimized for point-of-care use will prioritize rapid turnaround and simplified workflows, whereas imaging investments will focus on throughput, compatibility with stroke protocols, and integration with interventional teams. This multi-dimensional view supports targeted innovation and more effective deployment across diverse clinical settings.

Examining regional variations in infrastructure, clinical protocols, and adoption dynamics to align diagnostic strategies across diverse healthcare environments

Regional dynamics exert a profound influence on diagnostic adoption, infrastructure investment, and clinical protocols for acute ischemic stroke. In the Americas, advanced tertiary centers and integrated health networks often lead in deploying high-end imaging, mobile stroke units, and biomarker research, while rural regions within the same geography continue to face access challenges requiring telemedicine and hub-and-spoke models. In Europe, the Middle East & Africa, healthcare systems vary widely, with pockets of excellence in urban centers supported by public health initiatives that emphasize stroke networks, contrasted with areas where resource constraints necessitate pragmatic, scalable diagnostic solutions. In Asia-Pacific, rapid modernization of healthcare infrastructure and significant investments in imaging have expanded capacity, yet heterogeneity in reimbursement and workforce availability shapes differential uptake of advanced diagnostics.

These regional contrasts influence where vendors prioritize regulatory approvals, localization of service models, and partnerships with health ministries and hospital groups. Moreover, prevalence patterns, emergency medical services maturity, and regional training programs affect the feasibility of implementing advanced diagnostic workflows. Consequently, companies and health systems must craft regionally tailored strategies that consider infrastructure maturity, clinical practice norms, and the pragmatic needs of providers and patients across diverse settings.

Profiling the competitive landscape where integrated imaging, rapid assays, and software-enabled workflows converge to redefine diagnostic differentiation

Key companies competing in acute ischemic stroke diagnostics are advancing differentiated portfolios that span imaging hardware, laboratory assays, point-of-care platforms, and integrated software solutions. Market leaders complement established imaging platforms with software enhancements that improve workflow efficiency and quantitative interpretation, while innovative entrants concentrate on biomarker discovery, rapid assay formats, and compact diagnostic devices intended for emergency and pre-hospital use. Partnerships between imaging vendors, assay developers, and clinical institutions are increasingly common, enabling co-development of integrated diagnostic pathways that accelerate clinical validation and adoption.

Competitive dynamics also reflect a balance between scale and specialization. Large manufacturers leverage global service networks and established installation bases to sell bundled solutions that integrate scanners, informatics, and training. Meanwhile, agile startups often focus on niche performance advantages such as ultra-rapid assays or AI-enhanced image analysis, aiming to prove clinical impact through targeted trials and strategic collaborations. Overall, the competitive landscape rewards interoperability, regulatory foresight, and demonstrable improvements in diagnostic timelines and decision accuracy, creating opportunities for both consolidation and strategic alliances.

Actionable strategic priorities for developers and healthcare leaders to accelerate adoption and secure durable clinical and commercial advantages

Industry leaders should pursue a set of actionable priorities that accelerate clinical impact while managing operational risk. First, align product development with real-world clinical workflows by investing in interoperability, user-centered design, and training programs that reduce adoption friction. Second, prioritize clinical validation studies that demonstrate meaningful reductions in diagnostic time and improvements in treatment selection, thereby strengthening value propositions for payers and hospitals. Third, address supply chain vulnerabilities by diversifying manufacturing and distribution channels and by negotiating stable agreements that preserve access to critical components and reagents.

Furthermore, organizations should engage payer and regulatory stakeholders early to clarify reimbursement pathways and to design studies that meet evidentiary expectations. Strategic collaborations with emergency medical services, regional stroke networks, and academic centers can accelerate adoption and generate robust clinical data. Finally, invest in scalable service models and managed offerings that reduce total cost of ownership for health systems, and consider targeted commercialization strategies that match product tiering to the capacities of different end-users. Taken together, these actions will enhance market relevance while supporting clinicians in delivering faster, more accurate stroke diagnosis.

Describing a rigorous multi-source research approach combining clinical evidence, expert insights, and supply chain analysis to support robust conclusions

The research methodology integrates a multi-source approach combining clinical literature review, expert interviews, technology assessments, and supply chain analysis to produce a holistic view of the diagnostic landscape. Evidence synthesis draws on peer-reviewed clinical studies, guideline statements, and published technology evaluations to assess clinical utility and workflow implications. Interviews with neurologists, emergency physicians, radiologists, laboratory directors, and procurement leaders informed practical constraints and adoption drivers, while vendor briefings and product datasheets provided technical context on device capabilities and service models.

Supply chain and policy analyses relied on customs and trade documentation, procurement tender information, and public sector policy announcements to evaluate factors affecting equipment and reagent availability. Where appropriate, case examples from high-performance stroke centers illustrated best practices in pathway redesign and technology integration. Throughout the methodology, triangulation of multiple information streams ensured that conclusions reflect clinical realities, operational constraints, and technological trajectories relevant to acute ischemic stroke diagnosis.

Summarizing the converging clinical, technological, and operational forces that will determine diagnostic effectiveness and patient outcomes in acute stroke

In conclusion, acute ischemic stroke diagnosis is at an inflection point where technological innovation, pathway redesign, and supply chain considerations converge to reshape clinical practice. Rapid imaging, emergent biomarker applications, and point-of-care testing collectively enable more precise and timely decision-making, while regional and policy factors influence the feasibility and pace of adoption. Stakeholders who proactively address workflow integration, clinical validation, and procurement resilience will be best positioned to translate diagnostic advances into measurable improvements in patient outcomes.

Looking forward, the sustained focus on reducing time-to-treatment, combined with iterative improvements in diagnostic accuracy, will continue to drive investment and collaboration across clinical, commercial, and policy domains. By emphasizing interoperability, evidentiary rigor, and adaptive supply strategies, healthcare providers and industry partners can ensure that the next generation of diagnostic tools delivers both clinical value and operational sustainability for acute ischemic stroke care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-powered CT perfusion analysis to accelerate acute ischemic stroke diagnosis and triage
  • 5.2. Deployment of mobile stroke units equipped with portable CT scanners and telemedicine connectivity to reduce door-to-needle times
  • 5.3. Adoption of blood-based biomarker panels combined with AI algorithms for rapid differentiation of ischemic stroke subtypes
  • 5.4. Expansion of telestroke networks leveraging cloud-based imaging platforms to improve rural acute stroke patient outcomes
  • 5.5. Advancement in point-of-care molecular assays for real-time detection of neuroinflammatory markers in ischemic stroke patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Ischemic Stroke Diagnosis Market, by Product Type

  • 8.1. Blood Biomarker
  • 8.2. Carotid Ultrasound
  • 8.3. Diagnostic Imaging
    • 8.3.1. Computed Tomography (CT) Scanner
    • 8.3.2. MRI System
  • 8.4. Electroencephalography

9. Acute Ischemic Stroke Diagnosis Market, by Test Type

  • 9.1. Lab Tests
    • 9.1.1. Blood Test
    • 9.1.2. Imaging Tests
  • 9.2. Metabolic Panel

10. Acute Ischemic Stroke Diagnosis Market, by Disease Type

  • 10.1. Embolic
  • 10.2. Lacunar
  • 10.3. Thrombotic

11. Acute Ischemic Stroke Diagnosis Market, by Technology

  • 11.1. Biomarker-Based Detection
  • 11.2. Point Of Care Testing

12. Acute Ischemic Stroke Diagnosis Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals & Clinics
  • 12.4. Research Laboratories

13. Acute Ischemic Stroke Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Ischemic Stroke Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Ischemic Stroke Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Aidoc Medical Ltd.
    • 16.3.3. BIOTRONIK SE & Co KG
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. Boston Scientific Corporation
    • 16.3.6. Canon Medical Systems Corporation
    • 16.3.7. F. Hoffmann-La Roche Ltd.
    • 16.3.8. Fujifilm Holdings Corporation
    • 16.3.9. GE Healthcare Technologies Inc.
    • 16.3.10. Hitachi, Ltd.
    • 16.3.11. Integral Diagnostics (IDX) Group
    • 16.3.12. Johnson & Johnson Services, Inc.
    • 16.3.13. Koninklijke Philips N.V.
    • 16.3.14. Mediso Ltd.
    • 16.3.15. Medtronic PLC
    • 16.3.16. Merck & Co.
    • 16.3.17. Neusoft Corporation
    • 16.3.18. Nihon Kohden Corporation
    • 16.3.19. Planmed Oy
    • 16.3.20. Samsung Electronics Co. Ltd.
    • 16.3.21. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 16.3.22. Shimadzu Corporation
    • 16.3.23. Shionogi & Co., Ltd.
    • 16.3.24. Siemens Healthineers
    • 16.3.25. Stryker Corporation
    • 16.3.26. Toshiba International Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 281. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2024 (USD MILLION)
  • TABLE 286. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2025-2032 (USD MILLION)
  • TABLE 287. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2024 (USD MILLION)
  • TABLE 290. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2025-2032 (USD MILLION)
  • TABLE 291. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 296. GCC ACUTE ISCHEMIC STROKE DI